Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group

Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, 356, 115, 10.1056/NEJMoa065044

Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655

Motzer, 2013, Pazopanib versus sunitinib in metastatic renal-cell carcinoma, N Engl J Med, 369, 722, 10.1056/NEJMoa1303989

Abel, 2011, Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib, Eur Urol, 60, 1273, 10.1016/j.eururo.2011.07.008

Ferte, 2014, Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data, Eur Urol, 65, 713, 10.1016/j.eururo.2013.08.010

Heng, 2009, Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study, J Clin Oncol, 27, 5794, 10.1200/JCO.2008.21.4809

Motzer, 2002, Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma, J Clin Oncol, 20, 289, 10.1200/JCO.20.1.289

Motzer, 2006, Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma, J Clin Oncol, 24, 16, 10.1200/JCO.2005.02.2574

Rini, 2008, Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma, J Clin Oncol, 26, 3743, 10.1200/JCO.2007.15.5416

Gore, 2009, Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial, Lancet Oncol, 10, 757, 10.1016/S1470-2045(09)70162-7

Uemura, 2010, A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety, Jpn J Clin Oncol, 40, 194, 10.1093/jjco/hyp146

Choueiri, 2017, Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial, J Clin Oncol, 35, 591, 10.1200/JCO.2016.70.7398

Motzer, 2018, Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma, N Engl J Med, 378, 1277, 10.1056/NEJMoa1712126

Motzer, 2009, Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma, J Clin Oncol, 27, 3584, 10.1200/JCO.2008.20.1293

Ko, 2015, The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study, Lancet Oncol, 16, 293, 10.1016/S1470-2045(14)71222-7

Heng, 2013, External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study, Lancet Oncol, 14, 141, 10.1016/S1470-2045(12)70559-4

Kroeger, 2013, Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria, Cancer, 119, 2999, 10.1002/cncr.28151

Tanaka, 2016, External validation of the MSKCC and IMDC risk models in patients treated with targeted therapy as a first-line and subsequent second-line treatment: a Japanese multi-institutional study, Eur Urol Focus, 2, 303, 10.1016/j.euf.2015.11.001

Kwon, 2013, Validation of the MSKCC and Heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib, Ann Surg Oncol, 20, 4397, 10.1245/s10434-013-3290-1

Sella, 2017, Heterogeneity of patients with intermediate-prognosis metastatic renal cell carcinoma treated with sunitinib, Clin Genitourin Cancer, 15, 291, 10.1016/j.clgc.2016.08.013